| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2005;36:124.)
© 2005 American Heart Association, Inc.
Original Contributions |
From the Departments of Internal Medicine II (S.P., S.P.K., C. Kaun, W.S.S., T.W.W., S.D., H.S., K.H., G.M., J.W., M.G.-W.), Biomedical Engineering and Physics (C. Kollman), Pathology (R.U.), and Neurology (C.W., J.Z.), University of Vienna, Austria; and Institute of General Physics (B.D.-K., M.G., E.B.), Vienna University of Technology, Austria.
Correspondence to Dr Michael Gottsauner-Wolf, Department of Internal Medicine II, University of Vienna, A-1090 Vienna, Waehringer Guertel 18-20, Austria. E-mail michael.gottsauner-wolf{at}univie.ac.at
Background and Purpose Recently, 3 clinical trials revealed encouraging results in recanalization and clinical outcome in acute stroke patients when 2-MHz transcranial Doppler monitoring was applied. This study investigated whether a 1.8-MHz commercial diagnostic ultrasound device has the potential to facilitate thrombolysis using an in vitro stroke model.
Methods Duplex-Doppler, continuous wave-Doppler, and pulsed wave (PW)-Doppler were compared on their impact on recombinant tissue plasminogen activator (rtPA)mediated thrombolysis. Blood clots were transtemporally sonicated in a human stroke model. Furthermore, ultrasound attenuation of 5 temporal bones of different thickness was determined.
Results In comparison, only PW-Doppler accelerated rtPAmediated thrombolysis significantly. Without temporal bone, PW-Doppler plus rtPA showed a significant enhancement in relative clot weight loss of 23.7% when compared with clots treated with rtPA only (33.9±5.5% versus 27.4±5.2%; P<0.0005). Ultrasound attenuation measurements revealed decreases of the output intensity of 86.8% (8.8 dB) up to 99.2% (21.2 dB), depending on temporal bone thickness (1.91 to 5.01 mm).
Conclusion Without temporal bone, PW-Doppler significantly enhanced thrombolysis. However, because of a high attenuation of ultrasound by temporal bone, no thrombolytic effect was observed in our in vitro model, although Doppler imaging through the same temporal bone was still possible.
Key Words: middle cerebral artery stroke thrombolysis ultrasonography, Doppler, trnascranial
This article has been cited by other articles:
![]() |
J. Eggers, I. R. Konig, B. Koch, G. Handler, and G. Seidel Sonothrombolysis With Transcranial Color-Coded Sonography and Recombinant Tissue-Type Plasminogen Activator in Acute Middle Cerebral Artery Main Stem Occlusion: Results From a Randomized Study Stroke, May 1, 2008; 39(5): 1470 - 1475. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Reinhard, T. Els, and A. Hetzel Response to Letter by Gerriets et al Stroke, February 1, 2007; 38(2): 252 - 252. [Full Text] [PDF] |
||||
![]() |
F. Schneider, T. Gerriets, M. Walberer, C. Mueller, R. Rolke, B. M. Eicke, J. Bohl, O. Kempski, M. Kaps, G. Bachmann, et al. Brain Edema and Intracerebral Necrosis Caused by Transcranial Low-Frequency 20-kHz Ultrasound: A Safety Study in Rats Stroke, May 1, 2006; 37(5): 1301 - 1306. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Pfaffenberger, J. Wojta, and M. Gottsauner-Wolf High-Frequency Transtemporal Sonothrombolysis Stroke, July 1, 2005; 36(7): 1356 - 1357. [Full Text] [PDF] |
||||
![]() |
M. Daffertshofer, A. Gass, P. Ringleb, M. Sitzer, U. Sliwka, T. Els, O. Sedlaczek, W. J. Koroshetz, and M. G. Hennerici Transcranial Low-Frequency Ultrasound-Mediated Thrombolysis in Brain Ischemia: Increased Risk of Hemorrhage With Combined Ultrasound and Tissue Plasminogen Activator: Results of a Phase II Clinical Trial Stroke, July 1, 2005; 36(7): 1441 - 1446. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Meairs, C.-E. Dempfle, S. Pfaffenberger, W. S. Speidl, J. Wojta, and M. Gottsauner-Wolf In Vitro Models for Assessing Transcranial Ultrasound-Enhanced Thrombolysis * Response: Stroke, May 1, 2005; 36(5): 929 - 931. [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |